Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | President | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,305 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 24,576 · Balance 265,305 F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Of the shares of common stock reported, 193,254 shares represent restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Of the shares of common stock reported, 193,254 shares represent restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 24,576 | $4.44 | $109,228.03 |
DisclosureSEC source: 0001501697-26-000070 · wk-form4_1786651978.xml · nonDerivative · entry 1 Volpone John · CIK 0002081729 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,305 F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Of the shares of common stock reported, 193,254 shares represent restricted stock units. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 20:41 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 2,329,154 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0002081729-25-000003 · wk-form4_1761943317.xml · derivative · entry 1 Volpone John · CIK 0002081729 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,329,154 Underlying: Common Stock · 2,329,154 shares Expires 2035-08-12 F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 529,201 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · derivative · entry 3 Volpone John · CIK 0002081729 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,201 Underlying: Common Stock · 529,201 shares Expires 2035-08-14 F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 289,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · nonDerivative · entry 1 Volpone John · CIK 0002081729 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,881 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
| August 12, 2025 Filed Aug 15, 2025 00:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 1,609,873 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · derivative · entry 2 Volpone John · CIK 0002081729 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,609,873 Underlying: Common Stock · 1,609,873 shares Expires 2035-08-12 F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.